A previous clinical trial found that tamoxifen, taken for five years, reduced the risk of developing invasive breast cancer by about 50% in post-menopausal women who were at increased risk of getting the disease.
Another trial found that five years of raloxifene reduces breast cancer risk in such women by about 38%.
Under the new plans, high risk post-menopausal women could be offered the drugs for a period of five years unless they have a history of thromboembolic disease or endometrial cancer.
More top news
Pebble's new Time smartwatch has become the most funded project ever on crowd-funding site Kickstarter after raising more than £10 million.
A mother who revelled in the attention having a poorly child brought has been convicted of poisoning her son to death.
The Newcastle-based bakers made £1m a week in coffee sales in the period leading up to Christmas.